Results 241 to 247 of about 93,929 (247)

EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib

International Journal of Cancer, 2012
Zakaria Ezzoukhry, Christophe Louandre, Corinne Godin   +2 more
exaly  

Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis

Annals of Oncology, 2013
T Pressiani, C Boni, Lorenza Rimassa
exaly  

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

European Journal of Cancer, 2011
Masatoshi Kudo, Kazuho Imanaka, Kohei Nakachi   +2 more
exaly  

Sorafenib

Reactions Weekly
  +4 more sources

Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial

Annals of Oncology, 2016
Tosiya Sato, Atsushi Hagihara, S Nakamori   +2 more
exaly  

Sorafenib

Reactions Weekly, 2011
openaire   +2 more sources

Artesunate Sensitizes human hepatocellular carcinoma to sorafenib via exacerbating AFAP1L2-SRC-FUNDC1 axis-dependent mitophagy

Autophagy
Lingxiang Yu, Xia Mao, Fu-Neng Jiang
exaly